


Fidelity Special Values

Opportunities and value in an undervalued market

Fidelity Special Values (FSV) employs a value-based, contrarian investment style aiming to achieve long-term capital growth primarily through investment in UK companies, which the managers believe are undervalued or where potential has not been recognised by the market. FSV has endured a challenging period of underperformance. However, lead manager Alex Wright and co-manager Jonathan Winton believe the Q120 market sell-off created many investment opportunities, which they have sought to exploit. In their view, UK value stocks, and FSV in particular, now offer great value, which is further amplified by the trust's current discount making for a good valuation starting point for investment. The managers see significant scope for the trust to outperform not only growth strategies and UK equities in general, but also other asset classes.

Regaining ground – NAV performance versus the UK market



Source: Refinitiv, Edison Investment Research

The market opportunity

Value-based investment strategies have been out of favour with investors for some time, especially since the onset of the coronavirus crisis, when the market has focused on growth stocks, irrespective of valuations. In addition, UK equities are under-owned and trade at a significant discount to other equity markets. While this means that recent months have been painful for UK value investors, it has created a very attractive opportunity set, with significant upside potential.

Why consider investing in Fidelity Special Values?

- Recently improved performance and outperformance of the UK market over the long term.
- A value-based, contrarian investment approach offering style diversification and the opportunity for investors to benefit when investor sentiment towards value stocks improves and/or individual holdings re-rate on improved fundamentals or perceptions.

Recent shift to a discount with a 3.1% yield

FSV is currently trading at a discount of 9.2% to NAV, which compares with an average discount of 3.1% over one year, 1.3% over three years, and 2.9% and 5.9% over five and 10 years respectively. Based on the current share price, the trust offers a yield of 3.1%.

Investment trusts UK equities

14 October 2020


Price 184.0p
Market cap £532m
AUM £564m

NAV* 199.8p
Discount to NAV 9.2%


* Including income. As at 13 October 2020.

Yield 3.1%
Ordinary shares in issue 289.0m
Code FSV
Primary exchange LSE
AIC sector UK All Companies

Share price/discount performance



Three-year performance vs index



52-week high/low 280.5p 135.0p
NAV** high/low 275.5p 150.8p

**Including income.

Gearing

Gross market gearing 14.0%
Net market gearing 14.0%

*As at 31 August 2020.

Analysts

Joanne Collins +44 (0)20 3077 5000
Mel Jenner +44 (0)20 3077 5720

investmenttrusts@edisongroup.com




[Edison profile page](#)

Fidelity Special Values is a research client of Edison Investment Research Limited

Exhibit 1: Trust at a glance

Investment objective and fund background				Recent developments	
Fidelity Special Values' investment objective is to achieve long-term capital growth, primarily through investment in the equities of UK companies that the managers believe to be undervalued or where potential has not been recognised by the market. Investments are only made in companies where the potential downside risk is understood, to limit the possibility of losses. The trust's performance is measured against a broad index of UK companies.				<ul style="list-style-type: none"> 24 June 2020: Interim dividend of 2.10p per share paid. 28 April 2020: Six months results ended 29 February 2020. TR of -6.7% on a share price basis and -6.1% on an NAV basis, compared to -5.5% for the UK market. TR over five years was 42.5% on a share price basis and 29.8% on a NAV basis, compared to a benchmark return of 19.1%. 	
Forthcoming		Capital structure		Fund details	
AGM	December 2020	Ongoing charges	0.97%	Group	FIL Investments International
Final results	November 2020	Net market gearing	14% (as at 31 August 2020)	Manager	Alex Wright, Jonathan Winton
Year end	31 August	Annual mgmt fee	Tiered: 0.85% up to £700m net assets, 0.75% thereafter	Address	Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey KT20 6RP
Dividend paid	June, January	Performance fee	None	Phone	01732 361144
Launch date	17 November 1994	Trust life	Indefinite (subject to vote)	Website	www.fidelity.co.uk/specialvalues
Continuation vote	Three-yearly (2022)	Loan facilities	None – CFDs used		

Dividend policy and history (financial years)		Share buyback policy and history (financial years)	
Since 2015, FSV has paid interim and final dividends, in order to smooth the dividend payment for the year.		FSV has annually renewed authority to purchase up to 14.99% and allot up to 10% of its issued share capital.	



Top 10 holdings (as at 31 August 2020)			Portfolio weight %			
Company	Country	Sector	31 Aug 2020	31 Aug 2019*	Benchmark weight % 31 August 2020	Active weight % 31 Aug 2020
Legal & General Group	UK	Financials	5.4	4.5	1.0	4.4
Aviva	UK	Financials	4.2	4.4	0.0	4.2
Roche	Switzerland	Healthcare	3.7	N/A	0.7	3.0
Imperial Brands	UK	Consumer goods	3.6	3.8	0.2	3.4
Serco Group	UK	Industrials	3.6	4.1	0.1	3.5
DCC	UK	Industrials	3.3	N/A	0.7	2.6
ContourGlobal	UK	Utilities	3.2	4.4	6.4	(3.2)
Ultra Electronics Holdings	UK	Industrials	3.2	4.0	3.8	(0.6)
CRH	Ireland	Industrials	3.2	N/A	0.1	3.1
John Laing Group	UK	Financials	3.1	2.8	0.2	2.9
Top 10 (% of portfolio)			36.5	39.1		

Source: FSV, Edison Investment Research, Morningstar. Note: *N/A where not in end-August 2019 top 10.

The fund managers: Alex Wright and Jonathan Winton

The managers' view: Great value, with scope to outperform

FSV has a value-based, contrarian investment approach. Lead manager Alex Wright says that this investment style has been out of favour with investors for some time, but especially since the onset of the coronavirus. 'The market's focus during this pandemic has been very narrow, with attention primarily on companies with superior growth potential, seemingly irrespective of near-term uncertainty and certainly irrespective of valuations' he says. The manager views this as a challenging backdrop for contrarian investors, especially those, like FSV, focused on UK equities, which remain under-owned and which trade at a significant discount to other equity markets. 'Even steady companies with visible and relatively safe earnings are being overlooked' he says. In fact, Wright views 2020 as 'the worst year in history for value investing'.

However, he believes that current market conditions have a silver lining for value investors. 'There are now lots of amazing opportunities in value land, across many sectors', Wright says. He stresses that it is essential to be selective and focus on stocks with a margin of safety and evidence of positive change. But even in such cases, he believes that companies' fundamentals are often not reflected in valuations. The manager cites as one example FSV's holding in Sanofi, a pharmaceutical company, which has a credible COVID-19 vaccine under development yet has been overlooked by the market.

Wright also notes the unusually high level of uncertainty currently pervading financial markets in relation to the evolution of both the public health and associated economic crises. He expects the looming recession to be 'massive', despite the government's efforts to support jobs and activity, and views an effective vaccine as key to getting households and businesses to resume normal activity. The manager believes this uncertainty is further compounded by the government's failure to reach a deal with the EU over the UK's departure from the Union. 'A no-deal Brexit would be a negative outcome for the economy and financial markets, resulting in additional trade frictions and higher costs for companies', he says. However, Wright stresses that UK supply chains have proved robust through the coronavirus crisis, giving him comfort that a no-deal Brexit represents a lower risk than previously perceived, as companies are better prepared. Nonetheless, Brexit risks still need close monitoring, he warns. On a more positive note, the manager expects a successful outcome to Brexit negotiations to boost investor sentiment towards UK equities, and thus begin to redress the underperformance of the UK market in recent years.

On the broader question of value strategies' capacity to eventually reverse their underperformance against growth strategies, Wright notes that value stocks tend to experience sustained periods of outperformance in the early stages of economic recovery, as prices rise. 'Improved clarity on the economic outlook and Brexit, as well as a possible recalibration of rate expectations, may well be the catalyst for investors to broaden their investment horizons beyond the narrow range of secular growth stocks currently in favour', says Wright. A re-rating of value stocks may also be sparked by a shift in investor sentiment against growth stocks. 'Investor expectations regarding some growth stocks are now extremely high and lofty valuations leave little room for error', says Wright. 'If these companies fail to deliver on growth expectations, the market reaction is likely to be aggressive, with the potential to trigger a broader violent and sustained re-rating of value stocks.'

While it is impossible to predict the exact turning point for value strategies, Wright holds a strong conviction that investing in companies with attractive valuations has proved a rewarding strategy over the long term and he sees no reason why this should change going forward. 'At a time when not many assets are offering absolute returns, UK value stocks, and FSV in particular, look very attractive. The trust's appeal is amplified by its current discount, making for a good valuation

starting point for investment, with scope to outperform not only growth strategies and UK equities in general, but also other asset classes' he concludes.

The portfolio


Early in the coronavirus crisis, Wright took action to increase the defensiveness of the portfolio, closing positions in airlines and highly leveraged stocks. He also reduced exposure to oil stocks, given a sharp decline in the oil price and in anticipation of dividend cuts by UK oil majors. He sold Shell outright and reduced the position in BP, but maintains a 3.2% exposure to oil (as at end-August), as he expects the oil price to rise over time, supported by recovering demand and a lack of new investment in exploration.

More recently, Wright has begun responding to the many opportunities created by the market's uneven reaction to the pandemic. He has added several new names to the portfolio and topped up existing positions at attractive prices. Specifically, he has increased exposure to consumer spending in areas which have seen increased demand due to the pandemic, such as sportswear (Fraser Group), alternatives to public transport (Halfords and Inchape), online retailers (Studio Retail Group) and electronics and white goods suppliers (Dixons Carphone). Fraser and Halfords have both seen a like-for-like sales increase of around 25% year-on-year and surprised the market with better than expected results.

The virus-induced increase in demand for larger homes has motivated a greater exposure to house builders, both in the UK and Ireland, primarily focused on the construction of suburban houses, rather than city flats, where demand has declined in response to widespread remote working. Wright has also purchased a residential property services company, LSL Property Services, and increased exposure to life insurers, which he views as 'a very exciting sector' due to their growing earnings, strong balance sheets and low valuations. He believes life insurers are less cyclical than they were and that solvency levels have improved since the financial crisis. Furthermore, Wright sees further scope for beneficial strategic developments in this sector, which are not currently reflected in valuations. He has exposure to the life insurance sector via holdings in Legal and General and Aviva, the portfolio's two largest positions, which were increased during the sell-off, as well as in Phoenix and Just. The manager also added to other top 10 holdings in building materials company CRH and the fuel-to-medical products conglomerate DCC. Both were hit hard by the Q1 sell-off, but in Wright's view, retain their positive long-term prospects. The manager also added to the position in Serco, another top 10 holding and a company he believes has rehabilitated itself after previous problems and increased its government work, including some COVID-related contracts. Serco is one of a few companies to have increased its profit expectations this year. Wright notes that many of the portfolio's recent purchases have been smaller-cap companies, which he views as particularly attractive, as these have been more susceptible to uncertainty and have failed to benefit in the recent market recovery.

As a contrarian investor, Wright is not drawn to many of the high-profile technology and healthcare stocks that have become popular due to their perceived capacity to benefit from the coronavirus crisis. He views large pharma and medtech companies such as AstraZeneca, with valuations of around 25x earnings, as expensive. However, the portfolio does hold more attractively valued pharmaceutical names such as Sanofi and Roche (a top three holding), which trade at around 15x earnings, but have equally attractive drug pipelines and long-term prospects.

The manager has also reduced holdings in some stocks which have detracted from recent performance, including Meggitt, the aerospace equipment and maintenance supplier, and alcoholic drinks company C&C Group. Both these names were hit by the complete shutdown of their respective industries and face significantly reduced levels of activity while restrictions on movement and social gatherings continue. The manager has also sold Citigroup after a good performance, further reducing exposure to banks, whose near-term outlook is depressed by low interest rates.

Exhibit 2: Portfolio geographic and market cap exposure as at end-August 2020


Source: Fidelity Special Values, Edison Investment Research. Note: Figures are adjusted for gearing and index futures.

The portfolio presently has around 90–100 stocks – more than usual due to recent acquisitions. However, despite the increase in the number of holdings, portfolio concentration has remained unchanged since the beginning of the pandemic. At the end of August, the trust's top 10 holdings comprised 36.5% of the portfolio, the same level as at end-February 2020 and lower than 39.1% at end-August last year (Exhibit 1). The top 10 holdings are a mix of financials and industrials and other defensive businesses.

Exhibit 3: Portfolio sector exposure vs benchmark index (% unless stated)

	Portfolio end-August 2020	Portfolio end-August 2019	Change (pp)	Index end-August 2020	Active weight vs index (pp)	Trust weight/index weight (x)
Financials	28.7	28.2	0.5	25.6	3.1	1.1
Industrials	26.8	26.5	0.4	12.6	14.2	2.1
Consumer services	10.0	10.2	(0.2)	12.5	(2.5)	0.8
Healthcare	9.6	6.7	2.8	11.2	(1.6)	0.9
Consumer goods	8.7	8.3	0.4	15.1	(6.4)	0.6
Basic materials	6.5	7.2	(0.7)	8.9	(2.4)	0.7
Oil & gas	3.2	9.2	(6.0)	7.4	(4.2)	0.4
Utilities	3.1	2.9	0.2	3.3	(0.2)	0.9
Telecommunications	2.2	0.5	1.7	2.2	0.0	1.0
Technology	1.3	0.4	0.9	1.2	0.1	1.1
	100.0	100.0		100.0		

Source: Fidelity Special Values, Edison Investment Research. Note: Figures are adjusted for gearing and index futures. Numbers subject to rounding.

In terms of sectoral exposure, as shown in Exhibit 3, the portfolio's largest position is in financials (28.7%, representing an overweight of 3.1pp). This comprises mainly insurers, where the portfolio is overweight by about 8pp. Conversely, the portfolio is underweight banks, thanks in part to the recent disposal of Citigroup, as the manager sees the low interest rate environment as detrimental to banks' ability to generate interest income. Industrials are FSV's second largest position (26.8%) and the heaviest overweight (14.2pp), comprising a mix of aerospace, defence and support services and construction-related companies. The main sectoral underweight is to consumer goods (8.7% and 6.4pp underweight), partly because FSV's contrarian manager views many consumer staples such as Unilever, Diageo and Reckitt Benckiser as too expensive, compared to other defensive stocks. The trust is also underweight oil and gas (a 3.2% exposure, 4.2pp underweight) following the disposals discussed above. It has lesser underweights to consumer services, where the near-term outlook for many consumer-facing businesses such as restaurants, pubs and tourist venues is very poor, and to basic materials.

Portfolio net market gearing has increased to 14% at end-August 2020, from 2% at the same time last year, as the manager views gearing as a further means of capitalising on an usually broad set of superior quality opportunities. However, given the development of a second wave of the coronavirus and the unusual degree of uncertainty pervading the economic outlook, Wright is keen

to stress the well diversified nature of FSV’s portfolio positioning, which he expects to show resilience in the event of worse than expected public health or economic outcomes.

Performance: Improving, outperforming longer-term

Exhibit 4: Five-year discrete performance data


12 months ending	Share price (%)	NAV (%)	CBOE UK All Cos (%)	CBOE UK 100 (%)	CBOE UK 250 (%)	CBOE UK Small Cos (%)
30/09/16	5.0	14.3	17.4	0.9	11.1	3.8
30/09/17	24.9	20.0	12.0	0.9	14.2	23.6
30/09/18	14.7	7.0	5.9	0.8	4.6	1.4
30/09/19	(2.7)	(1.9)	2.7	0.8	(0.3)	(7.3)
30/09/20	(30.7)	(22.3)	(17.9)	(3.8)	(16.1)	(13.8)

Source: Refinitiv. Note: All % on a total return basis in pounds sterling.


FSV’s performance has been challenged for some time as its value-focused style has underperformed growth and momentum strategies. The coronavirus crisis caused this trend to accelerate. However, after what manager Alex Wright describes as an extremely painful Q120, where the portfolio was down 35.7% in NAV terms versus a market decline of 25.1%, the six-month period from 1 April to end September 2020 has seen performance improve. The fund made absolute gains of 3.9% on a share price basis and 13.5% in NAV terms, compared to a market return of 6.2%, as some of the portfolio’s defensive holdings demonstrated their resilience by surprising the market with stronger than expected results (Exhibit 5).

Exhibit 5: Investment trust performance to 30 September 2020

Price, NAV and index total return performance, one-year rebased



Price, NAV and index total return performance (%)



Source: Refinitiv, Edison Investment Research. Note: Three-, five- and 10-year performance figures annualised.

The portfolio’s overweight to ContourGlobal, a global utility business, which is a top 10 holding, has been one of the most significant contributors to performance over the last six months. While the manager expected it to do well in Q120, it took the market until Q2 to understand the nature of the business, particularly the fact that it has mainly fixed-price contracts. Wright has been engaged with this company for some time and was also aware that its attitude to environmental, social and governance (ESG) matters is changing. It recently announced that it has scrapped plans to build a coal-fired power station in Kosovo and committed to making no further coal plant investments globally. These announcements have seen the stock re-rating supported by ESG-conscious investors. FSV’s performance has also been assisted since April by the recovery in overweight positions in top 10 industrial companies CRH and DCC. Returns were also supported by an improvement in some small, idiosyncratic positions such as SEMAFO, a gold mining company which benefited from a takeover by Endeavour Mining and Indivior, a drug company whose stock price rallied after a court case was resolved in its favour. Recent performance has also been assisted by underweights in HSBC and oil companies Royal Dutch Shell and BP. The most significant detractors from performance over the last six months included overweight positions in

infrastructure company John Laing Group, tobacco company Imperial Brands and Roche, a pharmaceutical firm, which are all top 10 holdings, and Babcock International, an engineering services firm.

Exhibit 6: Share price and NAV total return performance, relative to indices (%)

	One month	Three months	Six months	One year	Three years	Five years	10 years
Price relative to CBOE UK All Companies	(1.9)	(3.7)	(2.1)	(15.6)	(13.4)	(13.6)	21.1
NAV relative to CBOE UK All Companies	(0.0)	2.5	6.9	(5.3)	(8.6)	(4.7)	19.7
Price relative to CBOE UK 100	(2.1)	(2.9)	8.5	(28.0)	(20.9)	2.0	89.9
NAV relative to CBOE UK 100	(0.3)	3.3	18.5	(19.2)	(16.6)	12.4	87.7
Price relative to CBOE UK 250	(0.4)	(7.9)	(8.8)	(17.4)	(11.7)	(8.7)	(7.2)
NAV relative to CBOE UK 250	1.4	(2.1)	(0.4)	(7.3)	(6.8)	0.7	(8.2)
Price relative to CBOE UK Small Companies	(0.3)	(7.3)	(9.5)	(19.7)	(4.7)	(2.5)	74.1
NAV relative to CBOE UK Small Companies	1.5	(1.4)	(1.2)	(9.9)	0.6	7.5	72.1

Source: Refinitiv, Edison Investment Research. Note: Data to end-30 September 2020. Geometric calculation.

This improvement in recent absolute and relative performance has so far been insufficient to make up for earlier underperformance and FSV's returns have lagged the broad UK market over one, three and five years. However, the trust has markedly outperformed the UK market in both share price and NAV terms over 10 years. The trust has also outperformed large-cap UK companies in both share price and NAV terms over five and 10 years, and small-cap UK companies over 10 years, as shown in Exhibit 6.

Exhibit 7: NAV total return performance relative to CBOE UK All Cos over three years



Source: Refinitiv, Edison Investment Research


Valuation: Discount management policy in action

As has been the case with many investment trusts, FSV's valuation has been volatile since the onset of the coronavirus pandemic. Its share price is currently trading at a discount of 9.2% to NAV, which compares with average discounts of 3.1%, 1.3%, 2.9% and 5.9% over the past one, three, five and 10 years respectively.

The trust's board seeks to maintain a single-digit discount or a small premium to NAV in normal market conditions. It has the authority to purchase up to 14.99% of shares in issue, which it believes gives shareholders a level of comfort. The board can also allot up to 10% of issued share capital. In FY19, c 9.6m shares (c 3.6% of the end-FY18 share base) were issued and, as shown in the share buyback chart in Exhibit 1, allotments accelerated in FY20 (ended 31 August 2020) with a total of 13.9m shares issued (c 5.0% of end-FY19 share base). So far in FY21, the board has repurchased c 1.0m shares into treasury.

The manager believes that the trust's move to a discount is not a surprise given its disappointing performance in Q120. He views the discount as offering an extra leg of performance potential as and when value strategies return to favour with investors.

Exhibit 8: Share price premium/discount to NAV (including income) over three years (%)



Source: Refinitiv, Edison Investment Research

Peer group comparison

FSV remains the second largest fund within the AIC UK all Companies sector. Its peers follow a variety of investment strategies. As shown in Exhibit 9, the trust's NAV total returns are below average across all periods shown, ranking 11th over one and three years, and 10th and 8th over five and 10 years respectively. Its share price discount to NAV is somewhat narrower than the average among its peers and its ongoing charge is higher. Like the majority of its peers, the trust does not pay a performance fee. The trust's level of gearing (14%) is second highest in the sector and its yield is slightly below the average, which is not surprising given that it is focused on capital growth rather than income.

Exhibit 9: AIC UK All Companies sector as at 13 October 2020*

% unless stated	Market cap £m	NAV TR 1 year	NAV TR 3 year	NAV TR 5 year	NAV TR 10 year	Discount (cum-fair)	Ongoing charge	Perf. fee	Net gearing	Dividend yield
Fidelity Special Values	532.0	(19.7)	(18.2)	9.6	95.4	(9.2)	1.0	No	114	3.1
Artemis Alpha Trust	115.8	3.1	2.7	22.7	43.7	(18.2)	1.0	No	100	1.8
Aurora	123.9	(13.9)	(11.1)	15.5	(21.5)	(3.7)	0.4	Yes	100	2.7
Baillie Gifford UK Growth	284.5	8.8	10.0	33.1	98.9	(5.4)	0.7	No	100	3.3
Henderson Opportunities	68.6	(0.3)	(6.3)	17.2	143.4	(19.0)	0.9	Yes	115	2.9
Independent	245.6	(2.6)	(9.7)	52.8	177.5	(11.0)	0.2	No	100	1.8
Invesco Perp Select UK Equity	42.5	(10.4)	(10.7)	10.3	136.9	(3.8)	0.9	Yes	113	4.6
JPMorgan Mid Cap	219.6	(6.5)	(3.9)	29.2	194.1	(14.1)	0.9	No	108	3.1
Jupiter UK Growth	28.5	(21.9)	(33.0)	(25.2)	11.2	(5.3)	1.2	Yes	99	4.4
Keystone	160.9	(12.8)	(13.6)	(2.1)	83.0	(17.5)	0.5	Yes	110	4.3
Mercantile	1,535.6	(2.8)	4.5	36.7	162.4	(8.8)	0.5	No	110	3.4
Schroder UK Mid Cap	177.1	(1.4)	1.5	31.2	169.8	(14.2)	0.9	No	106	3.7
Average (12 funds)	294.5	(6.7)	(7.3)	19.3	107.9	(10.9)	0.8		106	3.3
Trust rank in sector	2	11	11	10	8	6	2		2	8

Source: Morningstar, Edison Investment Research. Note: *Performance to 12 October 2020 based on ex-par NAV. TR = total return. Net gearing is total assets less cash and equivalents as a percentage of net assets.

General disclaimer and copyright

This report has been commissioned by Fidelity Special Values and prepared and issued by Edison, in consideration of a fee payable by Fidelity Special Values. Edison Investment Research standard fees are £49,500 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright: Copyright 2020 Edison Investment Research Limited (Edison).

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.

Frankfurt +49 (0)69 78 8076 960
Schumannstrasse 34b
60325 Frankfurt
Germany

London +44 (0)20 3077 5700
280 High Holborn
London, WC1V 7EE
United Kingdom

New York +1 646 653 7026
1185 Avenue of the Americas
3rd Floor, New York, NY 10036
United States of America

Sydney +61 (0)2 8249 8342
Level 4, Office 1205
95 Pitt Street, Sydney
NSW 2000, Australia